Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
President and CEO of ADMA Biologics NASDAQ:ADMA, Adam S. Grossman, sold 21,000 shares of common stock on August 15, 2025, for approximately $354,480. The shares were sold at a price of $16.88. The transaction comes as ADMA maintains strong financial health with a market capitalization of $4 billion and impressive revenue growth of 44% over the last twelve months. According to InvestingPro, the company operates with moderate debt levels and maintains healthy liquidity with a current ratio of 5.3.
On the same day, Grossman also exercised options to acquire 15,000 shares of ADMA Biologics common stock at a price of $5.40, for a total value of $81,000.
Following these transactions, Grossman directly owns 2,031,850 shares of ADMA Biologics. He also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
In other recent news, ADMA Biologics Inc reported its second-quarter 2025 earnings, which did not meet analyst expectations. The company announced an earnings per share (EPS) of $0.14, slightly below the forecasted $0.15. Additionally, ADMA Biologics reported revenues of $122 million, which fell short of the anticipated $124.13 million. These results highlight a minor shortfall in both earnings and revenue projections. Despite the earnings miss, there was no significant news about mergers or acquisitions during this period. Analyst firms have yet to provide any upgrades or downgrades following the earnings announcement. Investors may be attentive to future analyst updates for further insights. These developments are part of the recent updates concerning ADMA Biologics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.